Zhengye Biotechnology Holding Limited Class A Ordinary Shares
Here’s whether Zhengye Biotechnology Holding Limited Class A Ordinary Shares (ZYBT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 45 — healthy momentum range; 3-month momentum positive (+8.6%). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.95% over 10 days); weak 1-year return of -88.6%; rising volume on a downtrend (distribution, 2.21x avg). Currently 93.7% off its 52-week high. Score: -3/7.
ZYBT is trading below its 200-day MA ($2.19) — a key warning sign the longer-term trend is under pressure. An RSI of 44.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -88.6% compares to +22.9% for SPY (trailed the market by 111.5%). The current 93.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.